Stephen L. Garland

597 total citations
13 papers, 443 citations indexed

About

Stephen L. Garland is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Computational Theory and Mathematics. According to data from OpenAlex, Stephen L. Garland has authored 13 papers receiving a total of 443 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 4 papers in Cellular and Molecular Neuroscience and 4 papers in Computational Theory and Mathematics. Recurrent topics in Stephen L. Garland's work include Receptor Mechanisms and Signaling (5 papers), Computational Drug Discovery Methods (4 papers) and Chemical Synthesis and Analysis (3 papers). Stephen L. Garland is often cited by papers focused on Receptor Mechanisms and Signaling (5 papers), Computational Drug Discovery Methods (4 papers) and Chemical Synthesis and Analysis (3 papers). Stephen L. Garland collaborates with scholars based in United Kingdom, South Sudan and Spain. Stephen L. Garland's co-authors include David E. Gloriam, Frank E. Blaney, Steven M. Foord, P. M. Dean, Jason Witherington, John Liddle, Deirdre M. B. Hickey, Robert W. Ward, Vincent Bordas and David G. Smith and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Journal of Medicinal Chemistry and Chemical Science.

In The Last Decade

Stephen L. Garland

13 papers receiving 430 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen L. Garland United Kingdom	10	323	174	104	58	40	13	443
Zhan-Guo Gao United States	14	381 1.2×	130 0.7×	97 0.9×	79 1.4×	42 1.1×	22	541
Giles A. Brown United Kingdom	13	241 0.7×	122 0.7×	173 1.7×	39 0.7×	40 1.0×	17	455
Steven D. Heck United States	9	238 0.7×	125 0.7×	62 0.6×	33 0.6×	38 0.9×	10	405
Dorothée Möller Germany	15	577 1.8×	276 1.6×	55 0.5×	63 1.1×	46 1.1×	17	741
Manuela Jörg Australia	15	523 1.6×	245 1.4×	121 1.2×	66 1.1×	40 1.0×	36	667
Edward Rosser United Kingdom	5	367 1.1×	189 1.1×	40 0.4×	48 0.8×	40 1.0×	8	515
Marijke Somers Belgium	11	349 1.1×	184 1.1×	90 0.9×	34 0.6×	33 0.8×	16	494
Nisha K. Ramakrishnan Netherlands	12	401 1.2×	190 1.1×	65 0.6×	27 0.5×	80 2.0×	29	599
Saheem A. Zaidi United States	13	428 1.3×	278 1.6×	72 0.7×	51 0.9×	41 1.0×	27	549
Carmen Klein Herenbrink United States	12	585 1.8×	452 2.6×	67 0.6×	89 1.5×	69 1.7×	13	725

Countries citing papers authored by Stephen L. Garland

Since Specialization

Citations

This map shows the geographic impact of Stephen L. Garland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen L. Garland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen L. Garland more than expected).

Fields of papers citing papers by Stephen L. Garland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen L. Garland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen L. Garland. The network helps show where Stephen L. Garland may publish in the future.

Co-authorship network of co-authors of Stephen L. Garland

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen L. Garland. A scholar is included among the top collaborators of Stephen L. Garland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen L. Garland. Stephen L. Garland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Andrews, David, Paul Edwards, David Fox, et al.. (2016). The creation and characterisation of a National Compound Collection: the Royal Society of Chemistry pilot. Chemical Science. 7(6). 3869–3878. 5 indexed citations

Garland, Stephen L.. (2013). Are GPCRs Still a Source of New Targets?. SLAS DISCOVERY. 18(9). 947–966. 116 indexed citations

Garland, Stephen L. & David E. Gloriam. (2011). A Ligands View of Target Similarity: Chemogenomic Binding Site- Directed Techniques for Drug Discovery. Current Topics in Medicinal Chemistry. 11(15). 1872–1881. 14 indexed citations

Rocheville, Magalie & Stephen L. Garland. (2010). An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs. Drug Discovery Today Technologies. 7(1). e87–e94. 9 indexed citations

Barwell, James, et al.. (2009). Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. Biochemical and Biophysical Research Communications. 391(1). 437–442. 31 indexed citations

Corti, Corrado, Adelheid Roth, Annarosa Ugolini, et al.. (2009). The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorganic & Medicinal Chemistry Letters. 20(2). 759–762. 13 indexed citations

Wroblowski, Berthold, Mark Wigglesworth, Philip Szekeres, et al.. (2009). The Discovery of a Selective, Small Molecule Agonist for the Mas-Related Gene X1 Receptor. Journal of Medicinal Chemistry. 52(3). 818–825. 11 indexed citations

Gloriam, David E., Steven M. Foord, Frank E. Blaney, & Stephen L. Garland. (2009). Definition of the G Protein-Coupled Receptor Transmembrane Bundle Binding Pocket and Calculation of Receptor Similarities for Drug Design. Journal of Medicinal Chemistry. 52(14). 4429–4442. 80 indexed citations

Bamford, Mark J., Nicholas Bailey, Susannah Davies, et al.. (2005). (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(14). 3402–3406. 30 indexed citations

10.

Witherington, Jason, Vincent Bordas, Stephen L. Garland, et al.. (2003). 5-Aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorganic & Medicinal Chemistry Letters. 13(9). 1577–1580. 95 indexed citations

11.

Witherington, Jason, Vincent Bordas, Stephen L. Garland, et al.. (2003). 5‐Aryl‐pyrazolo[3,4‐b]pyridines: Potent Inhibitors of Glycogen Synthase Kinase‐3 (GSK‐3).. ChemInform. 34(31). 1 indexed citations

12.

Garland, Stephen L. & P. M. Dean. (1999). Design criteria for molecular mimics of fragments of the β-turn. 2. Cα–Cβ bond vector analysis. Journal of Computer-Aided Molecular Design. 13(5). 485–498. 14 indexed citations

13.

Garland, Stephen L. & P. M. Dean. (1999). Design criteria for molecular mimics of fragments of the β-turn. 1. Cα atom analysis. Journal of Computer-Aided Molecular Design. 13(5). 469–483. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact